argenx: cross-border access for the specialty portfolio

Quick orientation

argenx SE is a Belgian-Dutch biotechnology company headquartered in Ghent, Belgium, with US operations in Boston, Massachusetts. argenx is a focused FcRn-antagonist company. The current commercial footprint is anchored by a single molecule, efgartigimod, marketed in two formulations: Vyvgart (intravenous) and Vyvgart Hytrulo (subcutaneous co-formulation with hyaluronidase), across an expanding set of antibody-mediated autoimmune indications. The pipeline anticipates additional FcRn-antagonist indications in CIDP, immune thrombocytopenia subtypes, pemphigus, and myositis.

For Reserve Meds cross-border named-patient programs, argenx generates a focused but disproportionately high single-product (efgartigimod) demand because the molecule represents a new mechanism of action that has not been replicated by competitors and because the indication-expansion pace has outrun MENA and India local registration.

Portfolio in cross-border NPP scope

Vyvgart (efgartigimod alfa)

Neonatal Fc receptor (FcRn) antagonist approved for anti-AChR-antibody-positive generalized myasthenia gravis in adults, and with expanded indications in chronic inflammatory demyelinating polyneuropathy. The IV formulation is the original approval. US WAC at the standard treatment cycle (four weekly infusions, repeated as needed) has historically run at approximately $9,000 per dose. Cross-border requests cluster around gMG patients in MENA and India who have failed or are intolerant of standard immunosuppression and where Vyvgart has not yet been locally registered.

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)

The subcutaneous co-formulation of efgartigimod with recombinant human hyaluronidase, approved for generalized myasthenia gravis and CIDP. The subcutaneous formulation allows home administration and significantly reduces clinic burden compared to the IV form. International requests for Hytrulo come predominantly from gMG and CIDP patients who want home administration, particularly in the Gulf and India where the IV infusion-center burden is significant.

Pipeline molecules (not yet commercial)

argenx has FcRn-antagonist indications in development for primary immune thrombocytopenia, pemphigus vulgaris and foliaceus, myositis subtypes (dermatomyositis, polymyositis, immune-mediated necrotizing myopathy), and additional rare antibody-mediated diseases. As these receive FDA approval, Reserve Meds will expand cross-border NPP coordination to the new indications. For 2026, the focus remains gMG and CIDP.

Why patients route argenx products through cross-border NPP

The argenx cross-border driver is straightforward and concentrated. First, efgartigimod represents a novel mechanism (FcRn antagonism reduces circulating IgG via the natural antibody recycling pathway) that no other commercial product replicates. For gMG and CIDP patients who have failed conventional immunosuppression (steroids, azathioprine, mycophenolate, IVIG, plasmapheresis), efgartigimod is the on-label option.

Second, the local registration of Vyvgart in MENA and India has lagged the FDA approval and the indication-expansion (CIDP added in 2024). Patients meeting the FDA-labeled criteria often have no locally registered equivalent.

Third, the argenx My Tomorrow's Edge patient support program is restricted to US residents. International patients route as cash-pay.

Manufacturer engagement posture

Reserve Meds coordinates argenx-manufactured US product through DSCSA-compliant specialty wholesaler channels. We are not an authorized argenx distributor. All Reserve Meds orders are cash-pay at firm-quote pricing.

For argenx access, medical affairs, and international new product planning teams: Reserve Meds maintains structured demand visibility across the gMG and CIDP populations, with anticipated expansion to ITP, pemphigus, and myositis as those indications receive FDA approval. If your group is sizing pre-registration demand in MENA and India, particularly in advance of CIDP local launch or the upcoming pemphigus and myositis indications, we are open to a structured conversation under NDA.

Common cross-border destinations for the argenx portfolio

The gMG population concentrates in tertiary neuromuscular centers in the UAE, Saudi Arabia, India, and Egypt. The CIDP population tracks the same neurology specialist concentration. Vyvgart Hytrulo subcutaneous requests are heaviest from the Gulf where home administration logistics are most developed.

What Reserve Meds provides

For every argenx product order, Reserve Meds coordinates DSCSA chain-of-custody documentation; cold-chain validated logistics where required; country regulatory pathway expertise covering named-patient import approval, customs clearance, and any required physician declaration; and a single patient-facing coordinator. We do not replace the patient's treating physician. A US-licensed pharmacist reviews every prescription before dispensing.

Next step for patients

Patients or caregivers who have a treating physician's prescription for a argenx product and want a firm quote can start a request below.

Start a request for a argenx product

Next step for argenx teams

If you are on the argenx access, medical affairs, or international market access team and want to discuss coordinated named-patient program demand from MENA and India, reach us at [email protected]. We will share aggregated demand views under NDA.

Reserved for you.